SI3248969T1 - Postopek za pripravo N-(3-(aminometil)oksetan-3-il) karbamatnih intermediatov - Google Patents
Postopek za pripravo N-(3-(aminometil)oksetan-3-il) karbamatnih intermediatovInfo
- Publication number
- SI3248969T1 SI3248969T1 SI201531184T SI201531184T SI3248969T1 SI 3248969 T1 SI3248969 T1 SI 3248969T1 SI 201531184 T SI201531184 T SI 201531184T SI 201531184 T SI201531184 T SI 201531184T SI 3248969 T1 SI3248969 T1 SI 3248969T1
- Authority
- SI
- Slovenia
- Prior art keywords
- oxetan
- aminomethyl
- preparation
- carbamate intermediates
- carbamate
- Prior art date
Links
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| EP17176794.0A EP3248969B1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[3-(aminomethyl)oxetan-3-yl]carbamate intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3248969T1 true SI3248969T1 (sl) | 2020-07-31 |
Family
ID=52358790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531184T SI3248969T1 (sl) | 2014-01-24 | 2015-01-21 | Postopek za pripravo N-(3-(aminometil)oksetan-3-il) karbamatnih intermediatov |
| SI201531193T SI3097098T1 (sl) | 2014-01-24 | 2015-01-21 | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531193T SI3097098T1 (sl) | 2014-01-24 | 2015-01-21 | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (enExample) |
| EP (2) | EP3097098B1 (enExample) |
| JP (1) | JP6397501B2 (enExample) |
| KR (1) | KR101841866B1 (enExample) |
| CN (2) | CN109879837B (enExample) |
| AR (2) | AR099134A1 (enExample) |
| AU (1) | AU2015208244B2 (enExample) |
| BR (1) | BR112016016978B1 (enExample) |
| CA (1) | CA2934225C (enExample) |
| ES (2) | ES2788900T3 (enExample) |
| HR (2) | HRP20200715T1 (enExample) |
| IL (1) | IL245882B (enExample) |
| MX (1) | MX368110B (enExample) |
| MY (1) | MY176210A (enExample) |
| NZ (1) | NZ721534A (enExample) |
| PL (2) | PL3097098T3 (enExample) |
| RU (1) | RU2664643C2 (enExample) |
| SG (1) | SG11201605916QA (enExample) |
| SI (2) | SI3248969T1 (enExample) |
| WO (1) | WO2015110446A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| JP6779972B2 (ja) | 2015-07-16 | 2020-11-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 |
| NZ739226A (en) | 2015-07-22 | 2022-11-25 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| WO2017080967A1 (en) | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 架橋されたピペリジン誘導体 |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| US10881666B2 (en) | 2017-09-29 | 2021-01-05 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| KR20210138684A (ko) | 2019-03-18 | 2021-11-19 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| EP4037688A4 (en) | 2019-10-04 | 2023-09-06 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL HETEROCYCLIC COMPOUNDS |
| US20220387443A1 (en) * | 2019-10-31 | 2022-12-08 | Shanghai Ark Biopharmaceutical Co., Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| BR112023016970A2 (pt) | 2021-02-26 | 2023-10-10 | Enanta Pharm Inc | Compostos heterocíclicos antivirais |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2025011580A1 (zh) * | 2023-07-10 | 2025-01-16 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| MXPA05008108A (es) * | 2003-02-21 | 2005-09-21 | Pharmacia & Upjohn Co Llc | Exo-(2r)(+))-2-amino-7-azabiciclo[2.2.1]heptan-7-carboxilato de terc-butilo, compuestos intermedios y procedimiento para prepararlos y aislarlos. |
| EP1618094B1 (en) * | 2003-04-30 | 2007-09-05 | The Institutes for Pharmaceutical Discovery, LLC | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP2013534233A (ja) * | 2010-08-20 | 2013-09-02 | セルゾーム リミティッド | 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体 |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| ES2593059T3 (es) | 2011-10-11 | 2016-12-05 | F. Hoffmann-La Roche Ag | Compuestos para el tratamiento y profilaxis de enfermedad por virus sincitial respiratorio |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
| JP2016518421A (ja) * | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en not_active Ceased
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3248969T1 (sl) | Postopek za pripravo N-(3-(aminometil)oksetan-3-il) karbamatnih intermediatov | |
| SI3380530T1 (sl) | Izboljšan postopek za pripravo sugamadeksa in njegovih intermediatov | |
| IL250441A0 (en) | A method for the production of 5-fluoro-1h-pyrazoles starting from hexafluoropropane | |
| PT3717457T (pt) | Processo de preparação de enzalutamida utilizando um intermediário inovador | |
| IL248566B (en) | A process for the preparation of 5-fluoro-1h-pyrazoles from hexafluoropropane | |
| PT3102562T (pt) | Processo para a purificação de adipodinitrilo (adn) | |
| GB201416678D0 (en) | Process For Synthesizing Ergothioneine And Its Intermediates | |
| IL250211B (en) | A process for the preparation of optically active isoxazoline compounds | |
| PL4012035T3 (pl) | Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc) | |
| ZA201805871B (en) | An improved process for the preparation of lacosamide | |
| SI3565552T1 (sl) | Izboljšan postopek za pripravo rivaroksabana, ki vključuje nov intermediat | |
| IL255819A (en) | An improved process for the preparation of sofosbuvir and intermediates | |
| ZA201808387B (en) | Improved process for the preparation of carbamates | |
| ZA201701973B (en) | Process for the preparation of halo-substituted trifluoroacetophenones | |
| IL253077A0 (en) | Process and intermediates for the preparation of Fermpanel | |
| GB201510544D0 (en) | New synthesis of tapentadol-hci intermediates | |
| HUE053496T2 (hu) | Eljárás izocianátok elõállítására | |
| PT3102565T (pt) | Processos para a preparação de intermediários de raltegravir | |
| HUE052880T2 (hu) | Eljárás 10-dezacetil-baccatin III tisztítására | |
| GB201700012D0 (en) | Iodoacetylcholine synthesis method as pharmaceutical intermediates | |
| TH1501000743A (th) | กระบวนการสำหรับการสังเคราะห์ของสารมัธยันตร์ของสารปราบวัชพืช ฟลูซีโตซัลฟูรอน | |
| GB201711318D0 (en) | Drug intermediates o-acetaminophen synthesis method |